中东呼吸综合征抗病毒治疗研究进展

Progress on Candidate Anti-viral Therapies for Middle East Respiratory Syndrome(MERS)Infection

中东呼吸综合征冠状病毒(MERS-CoV)目前在全球传播至20多个国家,病死率高达35%左右。目前尚无特异有效的临床救治手段,针对MERS-CoV感染的治疗策略的研发和应用是世界范围内迫切需要解决的重要问题。本文针对MERS-CoV感染抗病毒治疗策略从药物治疗(包括临床批准药物、蛋白酶抑制剂、抗病毒肽及核酸类药物)和免疫治疗(包括恢复期血浆治疗和特异性单/多克隆抗体)两方面的研究进展进行综述。

Currently,more than two-thousand laboratory-confirmed cases of Middle East respiratory syndrome coronavirus(MERS-CoV)infection have been reported in more than twenty countries,with a case fatality rate of 35%.There is no specific and effective therapy until now.Therefore,the development of prophylactic and therapeutic strategy against MERS-CoV infection is an urgent problem.This article reviews the current and potential advances on drug therapy(including clinically approved drugs,protease inhibitors,antiviral peptides and nucleic acid drugs)and immunotherapy(including convalescent plasma therapy and specific monoclonal/polyclonal antibodies)for Middle East respiratory syndrome(MERS).